Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study Bousman, Chad A., Müller, Daniel J., Ng, Chee H., Byron, Keith, Berk, Michael and Singh, Ajeet B. 2017, Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study, Pharmacogenetics and genomics, vol. 27, no. 1, pp. 1-6, doi: 10.1097/FPC.0000000000000253. Attached Files Name Description MIMEType Size Downloads Title Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study Author(s) Bousman, Chad A. Müller, Daniel J. Ng, Chee H. Byron, Keith Berk, Michael orcid.org/0000-0002-5554-6946 Singh, Ajeet B. orcid.org/0000-0002-0853-7959 Journal name Pharmacogenetics and genomics Volume number 27 Issue number 1 Start page 1 End page 6 Total pages 6 Publisher Wolters Kluwer Health Place of publication London, Eng. Publication date 2017-01 ISSN 1744-6872 1744-6880 Summary Background Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. Objective To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. Materials and methods A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission. Results Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. Conclusion Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing. Language eng DOI 10.1097/FPC.0000000000000253 Field of Research 110319 Psychiatry (incl Psychotherapy) 0604 Genetics 1115 Pharmacology And Pharmaceutical Sciences Socio Economic Objective 920410 Mental Health HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2016, Wolters Kluwer Health Persistent URL http://hdl.handle.net/10536/DRO/DU:30090265 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 16 Dec 2016, 11:19:27 EST Fri, 16 Dec 2016, 11:21:21 EST Sat, 17 Dec 2016, 04:00:28 EST Fri, 20 Jan 2017, 05:04:52 EST Wed, 25 Jan 2017, 08:47:57 EST Wed, 25 Jan 2017, 08:50:49 EST Filtered Full Citation counts:   Cited 10 times in TR Web of Science Cited 11 times in Scopus Search Google Scholar Access Statistics: 389 Abstract Views, 2 File Downloads  -  Detailed Statistics Created: Fri, 16 Dec 2016, 11:21:21 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.